Feasibility study of zoledronic acid plus cisplatin-docetaxel as first-line treatment for advanced non-small cell lung cancer with bone metastases.

Abstract

BACKGROUND:

This study evaluated the safety and efficacy of combined zoledronic acid, cisplatin and docetaxel in patients with non-small cell lung cancer (NSCLC) with bone metastases.

PATIENTS AND METHODS:

Cisplatin 80 mg/m(2) and docetaxel 60 mg/m(2) with zoledronic acid 4 mg were given intravenously on day 1 every 3-4 weeks. The primary endpoint was feasibility of concomitant administration of zoledronic acid and cisplatin.

RESULTS:

Thirty-five chemonaïve patients were enrolled. The median number of treatment cycles was four, and two or more cycles were administered in 29 (83%) patients without severe toxicity. No grade 3 or 4 renal toxicity was observed. The objective response rate was 29% and the 1-year survival rate was 37%. The pain score improved in 77% of the patients after six weeks.

CONCLUSION:

The combination of zoledronic acid, cisplatin and docetaxel is well-tolerated with acceptable renal toxicity, and has modest activity as a first-line treatment of NSCLC patients with bone metastases.

• Authors: Kiyotaka Yoh, Kaoru Kubota, Hironobu Ohmatsu, Koichi Goto, Seiji Niho, Yuichiro Ohe
• Journal: Anticancer research (Anticancer Res) Vol. 32 Issue 9 Pg. 4131-5 (Sep 2012) ISSN: 1791-7530 [Electronic] Greece
• PMID: 22993373 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Diphosphonates
• Imidazoles
• Taxoids
• Docetaxel
• Zoledronic Acid
• Cisplatin

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Bone Neoplasms (drug therapy, secondary)
• Carcinoma, Non-Small-Cell Lung (drug therapy, pathology, secondary)
• Cisplatin (administration & dosage, adverse effects)
• Diphosphonates (administration & dosage, adverse effects)
• Docetaxel
• Female
• Humans
• Imidazoles (administration & dosage, adverse effects)
• Infusions, Intravenous
• Lung Neoplasms (drug therapy, pathology)
• Male
• Middle Aged
• Taxoids (administration & dosage, adverse effects)
• Zoledronic Acid